NASDAQ:ONEM • US68269G1076
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for 1LIFE HEALTHCARE INC (ONEM).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2022-10-27 | Credit Suisse | Downgrade | Outperform -> Neutral |
| 2022-08-15 | Jefferies | Downgrade | Buy -> Hold |
| 2022-07-27 | Stifel | Downgrade | Buy -> Hold |
| 2022-07-25 | Truist Securities | Downgrade | Buy -> Hold |
| 2022-07-22 | BTIG | Downgrade | Buy -> Neutral |
| 2022-07-22 | Deutsche Bank | Maintains | Hold |
| 2022-07-22 | SVB Leerink | Maintains | Market Perform |
| 2022-07-22 | Barclays | Downgrade | Overweight -> Equal-Weight |
| 2022-07-22 | Citigroup | Downgrade | Buy -> Neutral |
| 2022-07-12 | Deutsche Bank | Downgrade | Buy -> Hold |
| 2022-07-11 | Evercore ISI Group | Downgrade | Outperform -> In-Line |
| 2022-07-07 | BTIG | Upgrade | Neutral -> Buy |
| 2022-05-27 | Stifel | Initiate | Buy |
| 2022-05-09 | SVB Leerink | Maintains | Market Perform |
| 2022-05-05 | Citigroup | Maintains | Buy |
| 2022-02-25 | Deutsche Bank | Maintains | Buy |
| 2022-02-24 | Keybanc | Maintains | Overweight |
| 2022-02-24 | SVB Leerink | Maintains | Market Perform |
| 2022-02-24 | Morgan Stanley | Maintains | Overweight |
| 2022-02-24 | Piper Sandler | Maintains | Overweight |
| 2021-12-21 | JP Morgan | Maintains | Overweight |
| 2021-12-15 | Credit Suisse | Maintains | Outperform |
| 2021-11-09 | SVB Leerink | Maintains | Market Perform |
| 2021-11-04 | Keybanc | Maintains | Overweight |
| 2021-09-27 | SVB Leerink | Initiate | Market Perform |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 276.3M 29.90% | 377.6M 36.66% | 621.552M 64.61% | 1.065B 71.35% | 1.348B 26.57% | 1.675B 24.26% | 1.893B 13.01% | |
| EBITDA YoY % growth | -39.83M -13.64% | -51.63M -29.63% | -198.751M -284.95% | -150.067M 24.50% | -97.31M 35.16% | -59.857M 38.49% | 26.877M 144.90% | |
| EBIT YoY % growth | -54.1M -20.22% | -74M -36.78% | -245.247M -231.41% | -388.186M -58.28% | -309.578M 20.25% | -284.135M 8.22% | N/A | |
| Operating Margin | -19.58% | -19.60% | -39.46% | -36.45% | -22.97% | -16.96% | N/A | |
| EPS YoY % growth | N/A | -0.83 -116.13% | -1.60 -92.77% | -2.09 -30.59% | -1.91 8.77% | -1.62 14.92% | N/A |
All data in USD
| Q4 / 22 | Q1 / 23 | Q2 / 23 | Q3 / 23 | Q4 / 23 | Q1 / 24 | Q2 / 24 | Q3 / 24 | Q4 / 24 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.54 -7.51% | -0.50 -5.69% | -0.42 11.55% | -0.40 29.85% | -0.48 11.32% | -0.41 17.86% | -0.32 25.53% | -0.33 18.37% | -0.29 40.09% |
| Revenue Q2Q % growth | 280.65M 21.91% | 324.6M 27.74% | 338.59M 32.34% | 345.27M 32.10% | 366.27M 30.51% | 426.71M 31.46% | 435.23M 28.54% | 451.64M 30.81% | 494.86M 35.11% |
| EBITDA Q2Q % growth | -38.919M 21.14% | -25.299M 64.73% | -24.872M 54.56% | -19.57M 61.84% | -24.937M 35.93% | -23.809M 5.89% | -6.492M 73.90% | -6.071M 68.98% | 6.078M 124.37% |
| EBIT Q2Q % growth | -97.247M -1.46% | -88.292M 4.68% | -77.48M 20.46% | -79.285M 32.40% | -59.362M 38.96% | -79.282M 10.21% | -62.202M 19.72% | -63.882M 19.43% | -56.273M 5.20% |
All data in USD
20 analysts have analysed ONEM and the average price target is 18.55 USD. This implies a price increase of 12.6% is expected in the next year compared to the current price of 16.47.
1LIFE HEALTHCARE INC (ONEM) will report earnings on 2023-05-02.
The consensus EPS estimate for the next earnings of 1LIFE HEALTHCARE INC (ONEM) is -0.54 USD and the consensus revenue estimate is 280.65M USD.
The number of analysts covering 1LIFE HEALTHCARE INC (ONEM) is 20.